SG10201911548QA - Bispecific antibody constructs binding dll3 and cd3 - Google Patents
Bispecific antibody constructs binding dll3 and cd3Info
- Publication number
- SG10201911548QA SG10201911548QA SG10201911548QA SG10201911548QA SG10201911548QA SG 10201911548Q A SG10201911548Q A SG 10201911548QA SG 10201911548Q A SG10201911548Q A SG 10201911548QA SG 10201911548Q A SG10201911548Q A SG 10201911548QA SG 10201911548Q A SG10201911548Q A SG 10201911548QA
- Authority
- SG
- Singapore
- Prior art keywords
- bispecific antibody
- antibody constructs
- constructs binding
- dll3
- binding dll3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199930P | 2015-07-31 | 2015-07-31 | |
| US201662290896P | 2016-02-03 | 2016-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911548QA true SG10201911548QA (en) | 2020-01-30 |
Family
ID=56800252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911548QA SG10201911548QA (en) | 2015-07-31 | 2016-08-01 | Bispecific antibody constructs binding dll3 and cd3 |
Country Status (37)
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769948C2 (ru) * | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| KR102813659B1 (ko) | 2013-11-11 | 2025-05-28 | 추가이 세이야쿠 가부시키가이샤 | 개변된 항체 가변영역을 포함하는 항원 결합 분자 |
| TWI831044B (zh) | 2014-11-11 | 2024-02-01 | 日商中外製藥股份有限公司 | 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法 |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| EA201891753A1 (ru) | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| SG11201909160WA (en) | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| EP4029877B1 (en) | 2017-08-03 | 2024-01-17 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| JP7314146B2 (ja) * | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3774921A4 (en) * | 2018-04-03 | 2022-01-05 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT |
| EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| JP7479290B2 (ja) * | 2018-04-10 | 2024-05-08 | アムジエン・インコーポレーテツド | Ｄｌｌ３に対するキメラ受容体及びその使用方法 |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| MX2021000827A (es) | 2018-08-03 | 2021-03-25 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si. |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| US12509524B2 (en) | 2018-09-28 | 2025-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| JP7611820B2 (ja) * | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| PH12021551720A1 (en) | 2019-03-01 | 2022-03-28 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| CN113795262A (zh) * | 2019-04-08 | 2021-12-14 | 东莞凡恩世生物医药有限公司 | 人源化抗dll3嵌合抗原受体及其用途 |
| AU2020275002A1 (en) | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| MA56110A (fr) * | 2019-06-07 | 2022-04-13 | Amgen Inc | Constructions de liaison bispécifiques à lieurs clivables de manière sélective |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| WO2021011480A1 (en) * | 2019-07-12 | 2021-01-21 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind cxcr4 to modulate cellular function |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| JP7789002B2 (ja) | 2020-01-29 | 2025-12-19 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物 |
| US11976133B2 (en) * | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| US12486331B2 (en) * | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
| TW202200615A (zh) | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
| CR20220541A (es) | 2020-03-31 | 2022-11-28 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos |
| CA3173706A1 (en) * | 2020-04-29 | 2021-11-04 | Twinkle R. Christian | Pharmaceutical formulation |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| JP7518286B2 (ja) | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| CA3199319A1 (en) * | 2020-10-22 | 2022-04-28 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| CR20230229A (es) * | 2020-11-06 | 2023-09-05 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| MX2023012614A (es) * | 2021-05-08 | 2023-11-03 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Molecula de union contra dll3 y uso de la misma. |
| IL307646A (en) * | 2021-05-10 | 2023-12-01 | Amgen Inc | Dosing regimen for combination therapy targeting DLL3 and PD-1 |
| AU2022304662A1 (en) * | 2021-06-30 | 2023-11-23 | Amgen Inc. | Method of reconstituting lyophilized formulation |
| CN113461821B (zh) * | 2021-09-03 | 2021-12-28 | 苏州近岸蛋白质科技股份有限公司 | 抗cd3人源化抗体 |
| CN118234510A (zh) * | 2021-09-17 | 2024-06-21 | 上海药明生物技术有限公司 | D3结合分子及其用途 |
| WO2023053272A1 (en) | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| AU2023217790A1 (en) * | 2022-02-10 | 2024-08-22 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Bispecific antigen-binding molecule and use thereof |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| CN119256017A (zh) * | 2022-06-23 | 2025-01-03 | 江苏恒瑞医药股份有限公司 | 特异性结合dll3和cd3的抗原结合分子及其医药用途 |
| WO2024123965A2 (en) * | 2022-12-08 | 2024-06-13 | Amgen Inc. | Methods for treating dll3-expressing cancer |
| WO2025035356A1 (en) * | 2023-08-14 | 2025-02-20 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against dll3 and uses thereof |
| WO2025131024A1 (zh) * | 2023-12-22 | 2025-06-26 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合dll3和cd3的双特异性抗体的药物组合物 |
| WO2025146127A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 针对dll3和cd3的双特异性抗体及其应用 |
| WO2025190400A1 (zh) * | 2024-03-15 | 2025-09-18 | 福佑泰生物制药公司 | 抗dll3抗体及其用途 |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| WO2025252840A1 (en) | 2024-06-04 | 2025-12-11 | Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern | Half-life modulation by a tag comprising at least one constant domain of an immunoglobulin light chain |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
| WO2026060304A1 (en) | 2024-09-13 | 2026-03-19 | Amgen Inc. | Subcutaneous administration of anti-dll3 agent for treatment of cancer |
| WO2026075950A1 (en) | 2024-10-01 | 2026-04-09 | Amgen Inc. | Dosing regimen for anti-dll3 agent |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US5013A (en) | 1847-03-13 | Improvement in apparatus for the manufacture of malleable iron | ||
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US1985A (en) | 1841-02-18 | Charles m | ||
| US556A (en) | 1838-01-09 | Machine foe | ||
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| ATE108965T1 (de) | 1987-12-09 | 1994-08-15 | Omron Tateisi Electronics Co | Induktives datenübertragungssystem. |
| KR970008597B1 (ko) | 1987-12-28 | 1997-05-27 | 닛뽄 세키유가가쿠 가부시키가이샤 | 열가소성수지 조성물의 제조방법 |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| ES2142801T3 (es) | 1991-03-11 | 2000-05-01 | Univ Georgia Res Found | Clonacion y expresion de luciferasa de renilla. |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| AU4541093A (en) | 1992-06-18 | 1994-01-24 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US7045128B2 (en) | 1993-05-24 | 2006-05-16 | Immunex Corporation | Antibodies against flt3-ligand |
| EP0759170B1 (en) | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| KR100308764B1 (ko) | 1995-08-29 | 2001-12-17 | 마나배게이사꾸 | 키메라동물및그의제작법 |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP2002507410A (ja) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
| US7254167B2 (en) | 1998-10-30 | 2007-08-07 | Broadcom Corporation | Constellation-multiplexed transmitter and receiver |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
| EP2319301B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| US8486859B2 (en) | 2002-05-15 | 2013-07-16 | Bioenergy, Inc. | Use of ribose to enhance plant growth |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US7904068B2 (en) | 2003-06-06 | 2011-03-08 | At&T Intellectual Property I, L.P. | System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum |
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| EP2228698B1 (en) | 2005-03-14 | 2012-06-27 | Omron Corporation | Programmable controller system |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US8234145B2 (en) | 2005-07-12 | 2012-07-31 | International Business Machines Corporation | Automatic computation of validation metrics for global logistics processes |
| BRPI0604215A (pt) | 2005-08-17 | 2007-04-10 | Biosigma Sa | método para projetar oligonucleotìdeos para técnicas de biologia molecular |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2007122396A (ja) | 2005-10-27 | 2007-05-17 | Hitachi Ltd | ディスクアレイ装置及びその障害対応検証方法 |
| EP1960552A2 (en) * | 2005-12-16 | 2008-08-27 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US7919297B2 (en) | 2006-02-21 | 2011-04-05 | Cornell Research Foundation, Inc. | Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase |
| US7574748B2 (en) | 2006-03-07 | 2009-08-18 | Nike, Inc. | Glove with support system |
| US7990860B2 (en) | 2006-06-16 | 2011-08-02 | Harris Corporation | Method and system for rule-based sequencing for QoS |
| US8430938B1 (en) | 2006-07-13 | 2013-04-30 | The United States Of America As Represented By The Secretary Of The Navy | Control algorithm for autothermal reformer |
| KR101146588B1 (ko) | 2006-08-11 | 2012-05-16 | 삼성전자주식회사 | Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법 |
| CN100589507C (zh) | 2006-10-30 | 2010-02-10 | 华为技术有限公司 | 一种拨号提示系统及方法 |
| US7466008B2 (en) | 2007-03-13 | 2008-12-16 | Taiwan Semiconductor Manufacturing Company, Ltd. | BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US8209741B2 (en) | 2007-09-17 | 2012-06-26 | Microsoft Corporation | Human performance in human interactive proofs using partial credit |
| US8464584B2 (en) | 2007-10-19 | 2013-06-18 | Food Equipment Technologies Company, Inc. | Beverage dispenser with level measuring apparatus and display |
| DE112008003168B4 (de) | 2007-11-29 | 2022-01-05 | Schaeffler Technologies AG & Co. KG | Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb |
| US8376279B2 (en) | 2008-01-23 | 2013-02-19 | Aurora Flight Sciences Corporation | Inflatable folding wings for a very high altitude aircraft |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| CN102341172A (zh) | 2009-03-04 | 2012-02-01 | 日产自动车株式会社 | 废气净化催化剂及其制造方法 |
| US8463191B2 (en) | 2009-04-02 | 2013-06-11 | Qualcomm Incorporated | Beamforming options with partial channel knowledge |
| EP2493921B1 (en) | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| EP2658739B1 (de) | 2010-12-30 | 2017-02-22 | Johnson Controls Metals and Mechanisms GmbH & Co. KG | Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren |
| CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| NO2748201T3 (https=) | 2011-08-23 | 2018-05-12 | ||
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
| US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| CN104592392B (zh) * | 2015-01-21 | 2018-08-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| EP3174901B1 (en) * | 2014-07-31 | 2019-06-26 | Amgen Research (Munich) GmbH | Optimized cross-species specific bispecific single chain antibody constructs |
| UY36245A (es) * | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) * | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI717375B (zh) * | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA201891753A1 (ru) * | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| IL313507A (en) * | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2016
- 2016-07-29 TW TW105124267A patent/TWI793062B/zh active
- 2016-07-31 JO JOP/2016/0167A patent/JO3671B1/ar active
- 2016-08-01 EP EP24159281.5A patent/EP4382169A3/en active Pending
- 2016-08-01 UA UAA201801766A patent/UA126964C2/uk unknown
- 2016-08-01 KR KR1020227017868A patent/KR102749378B1/ko active Active
- 2016-08-01 MX MX2018001154A patent/MX385605B/es unknown
- 2016-08-01 PT PT167569508T patent/PT3328889T/pt unknown
- 2016-08-01 TN TNP/2017/000549A patent/TN2017000549A1/en unknown
- 2016-08-01 MA MA42530A patent/MA42530B1/fr unknown
- 2016-08-01 FI FIEP21153365.8T patent/FI3865514T3/fi active
- 2016-08-01 IL IL296409A patent/IL296409B2/en unknown
- 2016-08-01 KR KR1020247043230A patent/KR20250008981A/ko active Pending
- 2016-08-01 ES ES16756950T patent/ES2884211T3/es active Active
- 2016-08-01 CA CA2986848A patent/CA2986848C/en active Active
- 2016-08-01 PE PE2018000143A patent/PE20181152A1/es unknown
- 2016-08-01 NZ NZ737339A patent/NZ737339A/en unknown
- 2016-08-01 EP EP16756950.8A patent/EP3328889B1/en active Active
- 2016-08-01 MA MA71409A patent/MA71409A/fr unknown
- 2016-08-01 CN CN201680040701.5A patent/CN108271376B/zh active Active
- 2016-08-01 RS RS20211043A patent/RS62248B1/sr unknown
- 2016-08-01 JP JP2018504921A patent/JP6824245B2/ja active Active
- 2016-08-01 SI SI201631286T patent/SI3328889T1/sl unknown
- 2016-08-01 PL PL16756950T patent/PL3328889T3/pl unknown
- 2016-08-01 HU HUE16756950A patent/HUE055112T2/hu unknown
- 2016-08-01 DK DK16756950.8T patent/DK3328889T3/da active
- 2016-08-01 EP EP21153365.8A patent/EP3865514B1/en active Active
- 2016-08-01 SM SM20210482T patent/SMT202100482T1/it unknown
- 2016-08-01 KR KR1020247043229A patent/KR20250008980A/ko active Pending
- 2016-08-01 CN CN202411525134.5A patent/CN119371549A/zh active Pending
- 2016-08-01 CA CA3212157A patent/CA3212157A1/en active Pending
- 2016-08-01 US US15/225,107 patent/US10294300B2/en active Active
- 2016-08-01 AU AU2016302569A patent/AU2016302569B2/en active Active
- 2016-08-01 WO PCT/EP2016/068285 patent/WO2017021349A1/en not_active Ceased
- 2016-08-01 HR HRP20211073TT patent/HRP20211073T1/hr unknown
- 2016-08-01 IL IL320033A patent/IL320033A/en unknown
- 2016-08-01 MY MYPI2017704446A patent/MY184895A/en unknown
- 2016-08-01 MD MDE20180562T patent/MD3328889T2/ro unknown
- 2016-08-01 KR KR1020187000607A patent/KR102404077B1/ko active Active
- 2016-08-01 LT LTEPPCT/EP2016/068285T patent/LT3328889T/lt unknown
- 2016-08-01 CR CR20180066A patent/CR20180066A/es unknown
- 2016-08-01 SG SG10201911548QA patent/SG10201911548QA/en unknown
- 2016-08-01 CN CN202210020142.9A patent/CN114292336B/zh active Active
- 2016-08-01 EP EP25221787.2A patent/EP4706771A2/en active Pending
-
2018
- 2018-01-11 IL IL256871A patent/IL256871B2/en unknown
- 2018-01-26 MX MX2021009793A patent/MX2021009793A/es unknown
- 2018-01-29 CO CONC2018/0000877A patent/CO2018000877A2/es unknown
- 2018-01-30 CL CL2018000267A patent/CL2018000267A1/es unknown
- 2018-01-30 PH PH12018500241A patent/PH12018500241A1/en unknown
-
2019
- 2019-03-04 US US16/291,826 patent/US10683351B2/en active Active
-
2020
- 2020-05-06 US US16/868,257 patent/US11591396B2/en active Active
- 2020-07-27 JP JP2020126093A patent/JP6827583B2/ja active Active
- 2020-11-10 ZA ZA2020/06983A patent/ZA202006983B/en unknown
- 2020-11-25 CL CL2020003046A patent/CL2020003046A1/es unknown
-
2021
- 2021-01-19 JP JP2021006315A patent/JP7166368B2/ja active Active
- 2021-04-21 US US17/236,467 patent/US12304952B2/en active Active
- 2021-08-31 CY CY20211100778T patent/CY1124472T1/el unknown
-
2022
- 2022-10-25 JP JP2022170316A patent/JP7668256B2/ja active Active
- 2022-11-08 AU AU2022268314A patent/AU2022268314A1/en not_active Abandoned
- 2022-12-21 US US18/069,704 patent/US12435139B2/en active Active
-
2025
- 2025-04-08 AU AU2025202484A patent/AU2025202484A1/en active Pending
- 2025-04-14 JP JP2025066322A patent/JP2025106535A/ja active Pending
- 2025-04-24 US US19/188,628 patent/US20250340639A1/en active Pending
- 2025-11-27 AU AU2025271449A patent/AU2025271449A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006983B (en) | Bispecific antibody constructs binding dll3 and cd3 | |
| ZA201708306B (en) | Bispecific antibody constructs binding egfrviii and cd3 | |
| IL289946A (en) | Bispecific antibodies against cd3 and cd20 | |
| IL290517A (en) | cd3 binding antibodies | |
| IL256873A (en) | Constructs for bispecific antibodies that bind to masotilin and cd3 and uses thereof | |
| IL256870B (en) | Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof | |
| IL258036A (en) | Optimized bispecific antibodies against class 3 determinants and their uses | |
| IL255076A0 (en) | Bispecific antibody constructs for cdh3 and cd3 | |
| ZA201701341B (en) | Bispecific her2 and cd3 binding molecules | |
| IL256760B1 (en) | Human CD3-binding antibody |